Literature DB >> 17406654

Evaluation of reference regions for (R)-[(11)C]PK11195 studies in Alzheimer's disease and mild cognitive impairment.

Marc A Kropholler1, Ronald Boellaard, Bart N M van Berckel, Alie Schuitemaker, Reina W Kloet, Mark J Lubberink, Cees Jonker, Philip Scheltens, Adriaan A Lammertsma.   

Abstract

Inflammation in Alzheimer's disease (AD) may be assessed using (R)-[(11)C]PK11195 and positron emission tomography. Data can be analyzed using the simplified reference tissue model, provided a suitable reference region is available. This study evaluates various reference regions for analyzing (R)-[(11)C]PK11195 scans in patients with mild cognitive impairment (MCI) and probable AD. Healthy subjects (n=10, 30+/-10 years and n=10, 70+/-6 years) and patients with MCI (n=10, 74+/-6 years) and probable AD (n=9, 71+/-6 years) were included. Subjects underwent a dynamic three-dimensional (R)-[(11)C]PK11195 scan including arterial sampling. Gray matter, white matter, total cerebellum and cerebrum, and cluster analysis were evaluated as reference regions. Both plasma input binding potentials of these reference regions (BP(PLASMA)) and corresponding reference region input binding potentials of a target region (BP(SRTM)) were evaluated. Simulations were performed to assess cluster analysis performance at 5% to 15% coefficient of variation noise levels. Reasonable correlations for BP(PLASMA) (R(2)=0.52 to 0.94) and BP(SRTM) (R(2)=0.59 to 0.76) were observed between results using anatomic regions and cluster analysis. For cerebellum white matter, cerebrum white matter, and total cerebrum a considerable number of unrealistic BP(SRTM) values were observed. Cluster analysis did not extract a valid reference region in 10% of the scans. Simulations showed that potentially cluster analysis suffers from negative bias in BP(PLASMA). Most anatomic regions outperformed cluster analysis in terms of absence of both scan rejection and bias. Total cerebellum is the optimal reference region in this patient category.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17406654     DOI: 10.1038/sj.jcbfm.9600488

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  28 in total

1.  Decreased microglial activation in MS patients treated with glatiramer acetate.

Authors:  John N Ratchford; Christopher J Endres; Dima A Hammoud; Martin G Pomper; Navid Shiee; John McGready; Dzung L Pham; Peter A Calabresi
Journal:  J Neurol       Date:  2011-12-09       Impact factor: 4.849

Review 2.  Rubor, calor, tumor, dolor, functio laesa... or molecular imaging.

Authors:  Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-12       Impact factor: 9.236

3.  In vivo imaging of brain microglial activity in antipsychotic-free and medicated schizophrenia: a [11C](R)-PK11195 positron emission tomography study.

Authors:  S E Holmes; R Hinz; R J Drake; C J Gregory; S Conen; J C Matthews; J M Anton-Rodriguez; A Gerhard; P S Talbot
Journal:  Mol Psychiatry       Date:  2016-10-04       Impact factor: 15.992

4.  Validation of an automatic reference region extraction for the quantification of [18F]DPA-714 in dynamic brain PET studies.

Authors:  Daniel García-Lorenzo; Sonia Lavisse; Claire Leroy; Catriona Wimberley; Benedetta Bodini; Philippe Remy; Mattia Veronese; Federico Turkheimer; Bruno Stankoff; Michel Bottlaender
Journal:  J Cereb Blood Flow Metab       Date:  2017-02-09       Impact factor: 6.200

5.  In vivo imaging of the 18-kDa translocator protein (TSPO) with [18F]FEDAA1106 and PET does not show increased binding in Alzheimer's disease patients.

Authors:  Andrea Varrone; Patrik Mattsson; Anton Forsberg; Akihiro Takano; Sangram Nag; Balázs Gulyás; Jacqueline Borg; Ronald Boellaard; Nabil Al-Tawil; Maria Eriksdotter; Torsten Zimmermann; Marcus Schultze-Mosgau; Andrea Thiele; Anja Hoffmann; Adriaan A Lammertsma; Christer Halldin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-22       Impact factor: 9.236

Review 6.  In vivo PET imaging of neuroinflammation in Alzheimer's disease.

Authors:  Julien Lagarde; Marie Sarazin; Michel Bottlaender
Journal:  J Neural Transm (Vienna)       Date:  2017-05-17       Impact factor: 3.575

7.  Cerebellum Can Serve As a Pseudo-Reference Region in Alzheimer Disease to Detect Neuroinflammation Measured with PET Radioligand Binding to Translocator Protein.

Authors:  Chul Hyoung Lyoo; Masamichi Ikawa; Jeih-San Liow; Sami S Zoghbi; Cheryl L Morse; Victor W Pike; Masahiro Fujita; Robert B Innis; William Charles Kreisl
Journal:  J Nucl Med       Date:  2015-03-12       Impact factor: 10.057

Review 8.  Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers.

Authors:  Fabien Chauveau; Hervé Boutin; Nadja Van Camp; Frédéric Dollé; Bertrand Tavitian
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10-01       Impact factor: 9.236

9.  Statistical estimation of T1 relaxation times using conventional magnetic resonance imaging.

Authors:  Amanda F Mejia; Elizabeth M Sweeney; Blake Dewey; Govind Nair; Pascal Sati; Colin Shea; Daniel S Reich; Russell T Shinohara
Journal:  Neuroimage       Date:  2015-12-28       Impact factor: 6.556

10.  Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease.

Authors:  Clayton A Wiley; Brian J Lopresti; Sriram Venneti; Julie Price; William E Klunk; Steven T DeKosky; Chester A Mathis
Journal:  Arch Neurol       Date:  2009-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.